newsfilter
← Latest News
Business Wire·

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 Sensei Biotherapeutics, Inc.